

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kindstar Globalgene Technology, Inc.

康聖環球基因技術有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9960)

**DISCLOSEABLE TRANSACTION
AMENDMENTS TO PARTNERSHIP AGREEMENT**

Reference is made to the announcement of Kindstar Globalgene Technology, Inc. (the “**Company**”) dated November 12, 2023 (the “**Announcement**”) in relation to the formation of partnership. Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

AMENDMENTS TO PARTNERSHIP AGREEMENT

The Board of the Company hereby announces that on May 7, 2026, upon negotiation, all partners agreed to amend the Partnership Agreement. The details of the amendments are as follows:

Duration of the Partnership

The duration of the Partnership shall commence on the date of establishment as stated in the Partnership’s business license (i.e. December 20, 2023) and end on May 8, 2029. The Partnership has an investment period of 3 years commencing from the date of completion of the initial capital contribution (i.e. May 8, 2024) (the “**Investment Period**”) and a subsequent payback period of 2 years (the “**Payback Period**”). Upon the unanimous consent of the partners, the Investment Period and Payback Period may be extended but the maximum term shall not exceed 6 years in aggregate.

Management Fee

As the Investment Period is extended from 2 years to 3 years, the management fee for the extended one-year investment period (i.e. the third year of the Investment Period) will be calculated based on the standard applicable to the Payback Period (i.e. the annual management fee is 1.5% of the Fund's total cost of remaining investment as of the end of the previous year).

Save as disclosed above, all other terms set out in the Partnership Agreement remain unchanged.

By order of the Board
Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
HUANG Shiang
Chairman

Hong Kong, May 7, 2026

As of the date of this announcement, the Board comprises Dr. HUANG Shiang, Mr. TU Zanbing and Ms. CHAI Haijie as executive Directors, Mr. HUANG Zuie-Chin, Mr. PENG Wei, Ms. HUANG Lu and Dr. David Guowei WANG as non-executive Directors, and Dr. YAO Shanglong, Dr. XIA Xinping, Mr. GU Huaming and Dr. Gang WANG as independent non-executive Directors.